Publications scientifiques

Téléchargez nos documents

2016 Control of immune tolerance by the SIRPα - CD47 pathway and Myeloid-Derived Suppressor Cells: EACR 2016

2016 Selective targeting of the SIRPα immune checkpoint, but not CD47, controls the polarization of macrophages: EACR 2016

2016 Dual targeting of adaptive and innate checkpoints induce potent memory anti-tumor response: EACR 2016

2016 Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling: Cell

2016 Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade: Science

2015 Poster : T-cytotoxic specific immunotherapy in NSCLC with brain metastases: WCLC 2015

2015 Clinical efficacy of a new CD28-targeting antagonist of T cell co-stimulation in a non-human primate model of collagen-induced arthritis: Clinical and experimental Immunology

2015 Presentation : T-cytotoxic specific immunotherapy in NSCLC with brain metastases: WCLC 2015

2015 T cytotoxic specific immunotherapy in NSCLC with brain metastases: WCLC

2015 Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors: Cancer Biol Med

2015 Phase III, randomized trial of nivolumab versus docetaxel in advanced non-squamous cell NSCLC

2015 Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer: The New England Journal of Medicine

2015 Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC

2015 Optimizing PD-L1 as a biomarker of response with pembrolizumab as first-line therapy for PD-L1–positive metastatic NSCLC

2014 Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing: PubMed

2014 The Dual Role of Myeloid- Derived Suppressor Cells in Liver Pathologies: Journal of Liver and Clinical Research

2014 Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival: Genome Research

2013 Erlotinib versus docetaxel as second-line treatment of patients with advanced NSCLC and wild-type EGFR tumours

1 2 3 4